Ocular FIP treatment guidance points to higher-dose antiviral care

A growing body of evidence is sharpening how veterinarians think about ocular feline infectious peritonitis, with newer case series and guidance suggesting these cats often need more aggressive antiviral dosing than uncomplicated effusive disease. The most relevant recent report, an observational case series of 20 cats with ocular FIP, found most were started on injectable remdesivir and then transitioned to oral GS-441524, with higher-dose protocols commonly used and many cats showing improvement in ocular signs during treatment. That fits with broader clinical guidance that neurologic and ocular FIP cases often require escalated dosing because antiviral penetration into the eye can be more challenging. Recent clinical discussion has also emphasized that ocular FIP may be the dominant presentation in some cats, with uveitis, iris color change, keratic precipitates, hyphema, retinal lesions, or detachment sometimes serving as the first clue to systemic disease. In the U.S., this conversation has become more practical since compounded oral GS-441524 became available by prescription in June 2024 under FDA enforcement discretion for patient-specific use. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, ocular FIP is no longer just a grave diagnostic endpoint, but it is still a complicated treatment category. The key clinical shift is that eye involvement may signal the need for higher-dose antiviral therapy, close rechecks, and careful client counseling about treatment duration, monitoring, and cost. That is especially relevant as some clinicians explore whether higher-dose induction strategies and objective monitoring markers, such as acute phase proteins and albumin:globulin trends, can help guide duration more precisely rather than relying only on early clinical improvement. The evidence base is still evolving, but recent reviews and guidance suggest outcomes are generally better than they were a few years ago, even if cats with ocular or neurologic disease still tend to have lower overall success rates than the broader FIP population. (cliniciansbrief.com)

What to watch: Expect continued refinement of dose, duration, and drug-selection guidance for ocular and neurologic FIP as more prospective studies and consensus recommendations emerge, especially around induction dosing, stopping rules, and how adjunctive ophthalmic therapy affects outcomes. (abcdcatsvets.org)